Savolitinib

赛沃替尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameSavolitinib
Drug Alias Name沃利替尼SavolitinibumVolitinib沙伏替尼savolitinib +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitors
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursKidney Diseases +[23] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2021/06/22
Country/TerritoryBelgiumBulgariaCanada +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHutchison Medipharma Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAstrazeneca PlcNational Cancer InstituteAstrazeneca Ab +[5] 
Inactive CompaniesYale University
Active IndicationsGastroesophageal Junction NeoplasmsKidney DiseasesKidney Neoplasms +[14] 
Inactive IndicationsSolid tumoursRectal NeoplasmsColonic Neoplasms +[9] 

Other Information

ATC CodeL01XE
Related LinksN/A